Reader sentiment, not investment advice. One vote per visitor; click again to change it.
DMRA is priced at $20.22 right now, down 2.08% on the session. That puts its market value at $1.25B, 3093rd largest among the 3132 stocks we cover.
The 52-week range is $4.95 to $38.33. Today's price is about 46% of the way from the low to the high.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
DMRA is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Quote as of Oct 6, 2026 4:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$20.22 is the latest print for DMRA, a move of -2.08% against yesterday's close of $20.65. Today's low and high so far: $19.54 and $20.70.
Equity value comes to $1.25B at the current price. By that measure it is number 3093 of the 3132 names in our coverage.
The year's floor is $4.95 and the ceiling $38.33. Shares are 47.2% away from that ceiling.
Our data shows no dividend paid by Damora Therapeutics over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on DMRA.